Applications

1765 – Amendment of MBS items 73303 and 73304 (BRCA1/2 mutation testing in patients with metastatic castration-resistant prostate cancer) to include talazoparib

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type New application
  • Pre-PASC consultation Not applicable
  • Pre-MSAC consultation Closed
  • Outcome Supported

Application details

Reason for application

Amendment to MBS item.

Service or technology in this application

Testing of prostate tumour tissue (somatic) and germline to detect BRCA1/2 (BReast CAncer) gene mutations in men with metastatic castration-resistant prostate cancer, to determine their eligibility for treatment with PBS-listed Talazoparib.

Type: Investigative technology

Medical condition this application addresses

Prostate cancer is termed ‘castrate resistant’ when the disease progresses despite continuous androgen deprivation therapy. This application concerns the metastatic disease stage of prostate cancer, which constitutes a small proportion of the overall disease, and additionally targeting a subgroup of patients with genetic mutations in their homologous recombination repair genes.

Consultation survey and deadlines

  • PASC consultation: Not applicable
  • MSAC consultation: Closed Friday 16 February 2024

Meetings to consider this application

  • PASC meeting: Expedited - Bypassing PASC
  • ESC meeting: Expedited - Bypassing ESC
  • MSAC meeting: 4–5 April 2024